Newsletter Subscribe
Enter your email address below and subscribe to our newsletter
Research & Studies
Share your love
UC Irvine Study Links DNA Damage to AMD Progression
A groundbreaking study led by researchers at the University of California, Irvine, has identified accumulated DNA damage in the retina as a critical factor in the development of age-related macular degeneration (AMD). The findings, recently published in Aging Cell, could…
Cambium Bio Raises Funds for Dry Eye Trials
Cambium Bio Limited, a clinical-stage regenerative medicine company, announced that it has successfully completed an A$3.0 million capital raising round. This funding will primarily support the development of Elate Ocular, a novel treatment for dry eye disease (DED), through registration-enabling…
Galimedix Starts Phase 1 Trial for Oral GAL-101
Galimedix Therapeutics Inc. has announced the initiation of dosing in a Phase 1 clinical trial for oral GAL-101, an innovative amyloid beta (Aβ) aggregation modulator. The study aims to assess the therapy’s safety, tolerability, and pharmacokinetics, marking a significant step…
Ocular Therapeutix Progresses Phase 3 OTX-TKI Trial
Ocular Therapeutix has announced that over 300 patients have been randomized in the SOL-1 Phase 3 trial for OTX-TKI (AXPAXLI, axitinib intravitreal implant). This marks a critical milestone in the development of the first registrational trial for OTX-TKI as a…
Nicox Completes Denali Phase 3 Enrollment
Nicox has announced the completion of patient enrollment in China for the Denali Phase 3 trial, which evaluates the efficacy and safety of NCX 470 in patients with open-angle glaucoma or ocular hypertension. The screening process in China is now…
EPOMEC 2024: Ophthalmology Conference Highlights
The Evolving Practice of Ophthalmology Middle East Conference (EPOMEC) is set to take place from December 5–7, 2024, at the Dubai World Trade Centre, United Arab Emirates. This prestigious event brings together the latest advancements in ophthalmology from across the…
Prevent Blindness Offers GA Educational Materials
Prevent Blindness, a leading nonprofit organization dedicated to eye health, has announced its fourth annual Geographic Atrophy (GA) Awareness Week, taking place from December 2–8, 2024. Geographic Atrophy, an advanced form of dry age-related macular degeneration (AMD), affects an estimated…
AI-Ready Dataset Released for Type 2 Diabetes Research
A groundbreaking study has unveiled a flagship dataset designed to explore the biomarkers and environmental influences that contribute to the development of type 2 diabetes (T2D). This comprehensive dataset includes data from participants ranging from healthy individuals to those at…
ONS-5010 Falls Short in NORSE EIGHT Trial for Wet AMD
ONS-5010 (LYTENAVA), an ophthalmic formulation of bevacizumab for treating wet age-related macular degeneration (AMD), failed to meet the noninferiority endpoint in the NORSE EIGHT clinical trial, according to preliminary topline results announced by Outlook Therapeutics. About the NORSE EIGHT Trial…
Gene Editing Offers Hope for Retinitis Pigmentosa
Researchers funded by the National Eye Institute (NEI) have made significant strides in the treatment of retinitis pigmentosa (RP), a genetic disorder that causes progressive vision loss. Using a CRISPR-Cas9-based tool called base editing, the team corrected a specific mutation…